BRAF V600E VE1 antibody Abstracts summary sheet

VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations.

OBJECTIVES The VE1 monoclonal antibody was developed to recognize the V600E mutation in BRAF, which is found in various tumors. METHODS We report that the VE1 antibody stains normal anterior pituitary gland and adrenal cortex, which lack detectable BRAF V600E mutations. RESULTS Staining with the VE1 antibody was seen in the adenohypophysis and correlated well with adrenocorticotropic hormon...

Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation

BRAF mutation recently has been reported in metanephric adenoma. We sought to determine the clinical and morphologic features of BRAF-mutated metanephric adenoma and to correlate BRAF mutation with BRAF V600E immunohistochemical staining results. A series of 48 metanephric adenomas and 15 epithelial-predominant nephroblastomas were analyzed for the occurrence of BRAF mutation (BRAF V600E/V600E ...

White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-BRAF V600E (VE1) Antibody: A Comparison with Sanger Sequencing

White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-BRAF V600E (VE1) Antibody: A Comparison with Sanger Sequencing

Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.

Although sequencing provides the gold standard for identifying colorectal carcinoma with BRAF V600E mutation, immunohistochemistry (IHC) with the recently developed mouse monoclonal antibody VE1 for BRAF V600E protein has shown promise as a more widely available and rapid method. However, we identified anecdotal discordance between VE1 IHC and sequencing results and therefore analyzed VE1 stain...